Study of the safety of oral Triphala aqueous extract on healthy volunteers.

BACKGROUND: Triphala extract is a well known medicinal herbal formula which is usually prescribed by Thai traditional doctors to adjust the physiological functions of the body. Previous studies have reported that Triphala has antioxidant, anti-inflammatory, antihypercholesterolemia and anticancer properties. Though this herbal recipe is commonly used in Thailand, its human safety, especially in the oral form, has not been studied. We therefore conducted a clinical trial (Phase I). OBJECTIVE: This study evaluated the safety of administering the aqueous extract of Triphala to healthy volunteers at 2500 mg/d. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: An open-label, single-arm trial was conducted at Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand, between July 2017 and July 2018. The study enrolled 10 male and 10 female healthy volunteers; all were given Triphala (water extract; five capsules of 500 mg each) orally, once a day, at bedtime, for four consecutive weeks. MAIN OUTCOME MEASURES: Signs and symptoms, physical examinations, hematology and blood chemistry were assessed at the beginning of the trial and every week thereafter, for four consecutive weeks. After finishing the trial, on day 28, all volunteers were invited to a follow-up session on day 35 to evaluate the safety of the herbal recipe using the same measurements. RESULTS: At the oral dose of 2500 mg/d, Triphala had no serious adverse effects in healthy volunteers. Moreover, it was found to have significantly improved the volunteers' high-density lipoprotein cholesterol (HDL-C) levels on day 35 and also reduced their blood sugar levels on days 14 and 35. CONCLUSIONS: We conclude that aqueous extract of Triphala is safe for healthy volunteers and that it elevates HDL-C levels and lowers blood sugar. Further clinical study should investigate its effects on HDL-C and blood sugar levels among the dyslipidemic and prediabetic groups. TRIAL REGISTRATION: This trial was registered in the Thai Clinical Trial Registry with the identifier TCTR20180423002.

Pharmacological effects of Chatuphalatika in hyperuricemia of gout.

CONTEXT: Chatuphalatika (CTPT), is a Thai herbal formulation mixture of Phyllanthus emblica Linn. (Euphorbiaceae), Terminalia belerica Linn. (Combretaceae), T. chebula and the fruit of T. arjuna (Roxb.) Wight & Arn. CTPT is considered to exert anti-inflammatory and antihyperuricemic effects, but there have been no reports to demonstrate these pharmacological effects in a quantitative manner. OBJECTIVES: To investigate the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT. MATERIALS AND METHODS: Antioxidant activities of CTPT extracts were measured in vitro by DPPH, ABTS and FRAP assays, and anti-inflammatory effect by measuring inflammatory mediator production induced by lipopolysaccharide (LPS) in RAW264.7 macrophages. The mechanism of the hypouricemic effect was investigated using oxonate-induced hyperuricemic ddY mice treated with oral administrations of CTPT at 250, 500 and 1000 mg/kg. RESULTS: Antioxidant activities of CTPT measured by ABTS and FRAP assays were 1.35 g TEAC/g extract and 10.3 mmol/100 g extract, respectively. IC50 for the inhibition of DPPH radical was 13.8 µg/mL. CTPT (10 µg/mL) significantly downregulated the mRNA expression of TNF-α and iNOS in RAW 264.7 cells. Lineweaver-Burk analysis of the enzyme kinetics showed that CTPT inhibited xanthine oxidase (XOD) activity in a noncompetitive manner with the Ki of 576.9 µg/mL. Oral administration of CTPT (1000 mg/kg) significantly suppressed uric acid production by inhibiting hepatic XOD activity, and decreased plasma uric acid levels in hyperuricemic mice by approximately 40% (p < 0.05). CONCLUSIONS: This study demonstrated for the first time the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT in vivo and in vitro, suggesting a possibility of using CTPT for the treatment of hyperuricemia in gout.

Genetic variation of Croton stellatopilosus Ohba based on non-coding DNA sequences of ITS, trnK and trnL-F regions.

Croton stellatopilosus Ohba (Plau-noi), a well-known Thai medicinal plant, was investigated for its genetic variation by analyzing three DNA regions, one nuclear internal transcribed spacer (ITS) region and two chloroplast trnL-F intergenic spacer and trnK intron regions. The results of ITS sequencing from 30 leaf samples showed that there were two major genotypes of C. stellatopilosus which were designated as STEL Type A and B. In addition, various nucleotide additive sequences which had presumably arisen from these two groups were also found. These so-called "putative hybrids", interestingly, displayed trnK intron sequences identical to the STEL Type B but different from the Type A. For the trnL-F region, all the 30 samples showed identical sequences. Thus, it was suggested that in the hybridization of C. stellatopilosus, the Type A genotype acts as paternal parent whereas the Type B genotype acts as maternal parent. In addition, all C. stellatopilosus samples were analyzed for their plaunotol content using TLC densitometry. We found that the Type A genotype, hybrid group and Type B genotype had plaunotol content in the ranges 0.209-0.492, 0.319-0.896 and 0.442-1.000% (w/w) dry weight, respectively. The results indicated that there is a correlation between the plaunotol contents and non-coding DNA sequences of ITS, trnK and trnL-F regions of C. stellatopilosus.